Results 181 to 190 of about 25,067 (205)

Olaparib

Reactions Weekly, 2019
  +6 more sources

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Annals of Oncology, 2021
P A Fasching, T Link, J Hauke
exaly  

Olaparib

Drugs of the Future, 2009
null Vasiliou, S., null Castaner, R., null Bolos, J.   +2 more
openaire   +1 more source

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of Oncology, 2022
P Rastogi, G Aktan, S M Domchek
exaly  

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

Annals of Oncology, 2021
A Llop-Guevara, B Gilje, S Lundgren
exaly  

Two‐step flow synthesis of Olaparib in microreactor: Route design, process development and kinetics research

Chemical Engineering Journal, 2023
Qilin Xu, Zihao Wang, Yongjun Zang
exaly  

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Annals of Oncology, 2023
A Leary, J Mäenpää, G Bogner
exaly  

Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice

European Journal of Pharmaceutical Sciences, 2022
Yoo-Kyung Song, Min-Ju Kim, Min-Soo Kim   +2 more
exaly  

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Gynecologic Oncology, 2022
Nicoletta Colombo, Federica Tomao, Maria Ornella Nicoletto   +2 more
exaly  

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

Neuro-Oncology, 2020
Karen Strathdee, Catherine Mcbain, Anthony J Chalmers   +2 more
exaly